Balyasny Asset Management
NVCT icon

Balyasny Asset Management’s Nuvectis Pharma NVCT Stock Holding History

Balyasny Asset Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,483
Closed -$132K – 3194
2025
Q1 		$132K Buy
+13,483
New +$97.1K ﹤0.01% 2659

Other funds holding NVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Balyasny Asset Management's NVCT Position: Q2 2025 in Review

Balyasny Asset Management sold out of Nuvectis Pharma (NVCT) in Q2 2025, closing a stake of 13,483 shares — an estimated $132K sold.

Balyasny Asset Management first reported a position in NVCT in Q1 2025 and held it in 1 quarter. The position peaked at $132K in Q1 2025. 47 funds tracked by Wall St. Rank hold NVCT as of Q2 2025.

  • Balyasny Asset Management reported no remaining Nuvectis Pharma position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 13,483 Nuvectis Pharma shares in Q2 2025, an estimated $132K.
  • Balyasny Asset Management first reported a position in Nuvectis Pharma in Q1 2025 and held it in 1 quarter.
  • Balyasny Asset Management's Nuvectis Pharma position peaked at $132K in Q1 2025.
  • 47 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.